Despite the limited number of samples analyzed, and the lack of clear correlations between NRF2 and tumor grading or the survival of patients, the authors proposed that the molecular signature characterized by a high CUL3 and low NRF2 content might identify a cohort of patients more sensitive to chemical carcinogenesis but, also, to the use of chemotherapeutic drugs. This evidence concerns the gene NFE2L2 and neoplasm.